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Abstract We compared UCP3 protein in rat cardiac, glyco-
lytic and oxidative skeletal muscle and examined the e¡ect of
high-fat medium chain vs. long chain triacylglycerol feeding on
UCP3 content in these tissues. Cardiac muscle displays the low-
est basal levels of UCP3 protein. Increasing long chain ^ but not
medium chain ^ fatty acid supply upregulates UCP3 in all
muscles. Since plasma non-esteri¢ed fatty acids and the expres-
sion of two peroxisome proliferator-activated receptor (PPAR)-
responsive genes, were not di¡erent between groups, we con-
clude that the di¡erential upregulation of UCP3 is not merely
PPAR-mediated. This study supports a role of UCP3 in export
of non-metabolizable fatty acids.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The function of UCP3 is still under debate but there is
increasing evidence that the primary physiological role of
UCP3 is in fatty acid metabolism. Evaluation of the available
data on UCP3 expression shows that skeletal muscle UCP3 is
upregulated in situations where fatty acid supply exceeds fat
oxidative capacity such as acute fasting [1], high-fat diet [2^4]
and acute exercise [5]. On the other hand UCP3 is downregu-
lated in situations where fat oxidation capacity is improved
like endurance training [6,7] or during weight reduction [8,9].
In conditions where fatty acid supply exceeds fat oxidation
capacity, non-esteri¢ed fatty acids will accumulate in the cy-
tosol and might enter the mitochondrial matrix through £ip-
£op [6,10^12]. Based on these ¢ndings, we and others hy-
pothesized that the physiological function of UCP3 is to pro-
tect mitochondria from accumulation of non-esteri¢ed fatty
acids inside the mitochondrial matrix, especially in situations
where fatty acid delivery exceeds oxidation capacity [6,12,13].
In accordance with this hypothesis it was found that skel-
etal muscle with the lowest fat oxidative capacity (glycolytic,
type 2b muscle ¢bers) display the highest UCP3 mRNA and
protein levels while oxidative muscles (type 1 muscle ¢bers)
only moderately express UCP3 [14,15]. In this context, it is
interesting to note that cardiac muscle (CM), which mainly
depends on fatty acids for its energy supply, also expresses
UCP3 mRNA [16,17] and protein [16], while the level of
UCP3 protein relative to skeletal muscle is unknown. As
CM has a very high capacity to oxidize fatty acids, we hy-
pothesize that it contains UCP3 at levels even lower than in
type 1 muscle ¢bers. Therefore, the ¢rst aim of the present
study was to determine UCP3 protein levels in rat CM and to
compare these levels with UCP3 levels in the white gastroc-
nemius (WGM; mainly glycolytic) and soleus (SM; mainly
oxidative) muscle.
Additional support for a role for UCP3 in fat metabolism
comes from the ¢nding that prolonged consumption of a
high-fat diet upregulates skeletal muscle UCP3 mRNA and
protein levels, both in humans [2,4] and rodents [3,18]. During
high-fat feeding, fatty acid supply exceeds the oxidative ca-
pacity and fatty acids are likely to accumulate in the cytosol.
As a result, the entry of non-esteri¢ed fatty acids into the
mitochondrial matrix most likely increases and the observed
upregulation of UCP3 may facilitate outward transport of
these non-metabolizable fatty acids. Therefore, it is of rele-
vance to study the e¡ect of high-fat feeding on UCP3, at the
protein level, in muscles with di¡erent fat oxidative capacities.
We recently showed that the upregulation of UCP3 in
WGM upon high-fat feeding in rats is speci¢c for long chain
triacylglycerols (LCT) and completely absent when equal
amounts of medium chain triacylglycerols (MCT) are pro-
vided [19]. Because of their chain-length, medium chain fatty
acids (MCFA), in contrast to long chain fatty acids (LCFA),
do not rely on the carnitine shuttle system for their transport
across the mitochondrial membranes. In addition, they can be
readily oxidized inside the matrix because of the presence of a
matrix-associated enzyme which allows the activation and
subsequent L-oxidation of MCFA [20]. Therefore, upregula-
tion of UCP3 upon high-fat MCT feeding would be redun-
dant since non-esteri¢ed MCFA that enter the mitochondrial
matrix can still be oxidized. Here, we extend our previous
¢nding [19] and examine the e¡ect of high-fat, MCT vs.
LCT feeding on UCP3 protein content in the three earlier
mentioned muscles with di¡erent oxidative capacity. In addi-
tion, we examined whether the lack of e¡ect of MCT on
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UCP3 could be due to di¡erential peroxisome proliferator-
activated receptor (PPAR)-induced UCP3 gene regulation.
The promoter of UCP3 contains a PPAR-responsive element
[21], and LCFA are identi¢ed activators of PPARs while
MCFA activate PPARs to a much lesser extent [22,23].
Hence, it could be argued that the lack of upregulation of
UCP3 on a diet comprised of mainly MCTs merely re£ects
the lack of PPAR responsiveness to MCTs rather than a func-
tional adaptation of UCP3 to the increased mitochondrial
LCFA supply.
Therefore, the ¢nal aim was to study the gene expression of
UCP3 as well as two other, well-established, PPAR-responsive
genes, acyl-CoA synthetase (ACS) and long chain acyl-CoA
dehydrogenase (LCAD), upon high-fat MCT or LCT feeding.
2. Material and methods
2.1. Animals
Thirty male, 10 week old Wistar rats (Charles River) were housed
individually on a 12:12 h light^dark cycle (light from 7.00 h to
19.00 h), at 21^22‡C and subjected to a 2 week dietary intervention.
During the experiments, rats had free access to tap water. All experi-
ments were approved by the Institutional Animal Care and Use Com-
mittee of the Maastricht University and complied with the principles
of laboratory animal care.
2.2. Diets
Rats were randomly divided into three di¡erent groups (n=10).
Group 1 (LF LCT) received the low-fat control diet (7 net energy
(EN)% from fat) for the duration of 2 weeks. Group 2 (HF MCT)
was maintained on a high-fat MCT diet while group 3 (HF LCT)
received a high-fat LCT diet (both 46 EN% from fat). Diet speci¢ca-
tions are displayed in Table 1. All diets were purchased from Hope
Farms (Woerden, The Netherlands) and provided ad libitum. Food
intake and body mass were recorded daily.
To check net energy intake in the high-fat groups, diet and fecal
samples were analyzed for gross energy content using adiabatic bomb
calorimetry. Basal di¡erences in UCP3 protein concentrations be-
tween WGM, SM and CM were compared in four rats of the low-
fat control group.
2.3. Tissue sampling
After the 2 week dietary intervention period, tissue dissection was
performed under ketamine (Nimatek0 1.0 ml/kg) and xylazine
(Sedamun0 0.5 ml/kg) anesthesia upon short-term (less than 20 s)
CO2 sedation. Both anesthetics were injected subcutaneously. Rats
were deprived from food approximately 6 h prior to tissue sampling.
CM and the mid-belly regions of the WGM and SM were dissected
and immediately frozen in liquid nitrogen. Furthermore, a blood sam-
ple was collected in EDTA-containing Eppendorf tubes and plasma
was prepared by centrifugation at 10 000Ug for 2 min. Plasma sam-
ples were also frozen in liquid nitrogen. All samples were stored at
380‡C until analysis.
2.4. Non-esteri¢ed fatty acids
Plasma samples were analyzed for total non-esteri¢ed fatty acids
using the Wako NEFA C test kit (Wako Chemicals, Neuss, Ger-
many).
2.5. Analysis of mRNA expression
Northern blot analysis of mRNA was performed as described else-
where [24]. Speci¢cally, ¢lters were probed with a 0.7 kb fragment of
rat UCP3 generated via reverse transcriptase PCR using forward (5P-
GGCCATCCTCCGGAACCATGG-3P) and reversed (5P-GCGGCC-
TGCTTGCCTTGTTCA-3P) primers, a 520 bp EcoRV^HindIII frag-
ment of ACS (gift from Dr. T. Yamamoto, Tohoku University, Sen-
dai, Japan), and a 1390 bp EcoRI fragment of rat LCAD (a gift from
Dr. K. Tanaka, Yale University, USA).
2.6. UCP3 protein content
Western blot analysis of UCP3 protein was performed as described
elsewhere [19]. The a⁄nity puri¢ed polyclonal antiserum against
rUCP3 (code 1338, kindly provided by L.J. Slieker, Eli Lilly) was
raised in a rabbit against a 20 amino acid peptide that comprised
amino acids 147^166 of rat UCP3 (rUCP3). The puri¢ed antiserum
was tested extensively for speci¢city in immunoblotting assays using
positive and negative controls (i.e. brown adipose tissue, skeletal
muscle and UCP3 knock-out mice). Since the rUCP3 antiserum shows
cross reactivity with human tissues, the reactivity and speci¢city of
this antiserum was compared with the hUCP3 polyclonal antiserum
[15], both resulting in a UCP3 product of 33 kDa in human skeletal
muscle. After pre-incubation of the antibody with the peptide, the
speci¢c 33 kDa UCP3 protein band was absent.
2.7. Statistical analysis
Results are presented as meanRS.E.M. UCP3 levels upon control
feeding were set at 100 arbitrary units. Di¡erences between groups
were evaluated by analysis of variance (one-way ANOVA). When
signi¢cant di¡erences were found, a Bonferroni adjusted post-hoc
test was used to determine the exact location of the di¡erence. Out-
comes were regarded as statistically signi¢cant if P6 0.05.
3. Results
3.1. Gain of body mass and energy intake
By the end of the 2 week dietary intervention period, the
gain of body mass in the HF LCT group was 53.0 R 1.5 g/2
weeks, which was signi¢cantly higher than in the LF LCT
(45.3 R 1.0 g/2 weeks; P=0.034) and HF MCT (44.6 R 2.9
g/2 weeks; P=0.018) groups (Table 2). Gross energy intake
over the 2 week period was also signi¢cantly higher in the HF
LCT group (5727R 116 kJ/2 weeks) compared to the LF LCT
(4824R 88 kJ/2 weeks; P6 0.001) and HF MCT (4434R 124
kJ/2 weeks; P6 0.001) groups (Table 2). There was a trend
(P=0.06) towards a higher gross energy intake in the LF LCT
group in comparison with the HF MCT group. However,
Table 1
Major components and fatty acid composition of triacylglycerols in experimental diets
Diet Group 1: LF control Group 2: HF MCT Group 3: HF LCT
Protein (EN%) 19 19 19
Carbohydrates (EN%) 74 35 35
Fat (EN%) 7 46 46
Fatty acid pro¢le % of total fat % of total fat % of total fat
C8:0 60.0
C10:0 0.5 40.0 0.5
C14:0 1.0 1.0
C16:0 79.0 79.0
C18:0 6.0 6.0
C18:1 12.0 12.0
C18:2 1.0 1.0
Minerals and vitamins were added in order to provide 100% of AIN requirements for rats.
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adiabatic bomb calorimetry of the fecal samples of both high-
fat groups revealed that the amount of energy lost in the feces
was signi¢cantly higher in the HF LCT group compared to
the HF MCT group (1514R 45 vs. 477R 23 kJ/2 weeks;
P6 0.001) As a result, net energy intake in the HF LCT
group was not di¡erent from the HF MCT group over the
2 week intervention period (4214R 87 vs. 3956R 116 kJ; NS).
Therefore, the net energy intake per gram gain of body mass
was signi¢cantly higher in the HF MCT group (90.8 R 4.1
kJ/g) than in the HF LCT group (79.9 R 1.6 kJ/g; P=0.024,
Table 2), indicating that energy expenditure was increased on
the HF MCT diet.
3.2. Plasma free fatty acids
After 2 weeks of dietary intervention, plasma non-esteri¢ed
fatty acid levels averaged 201R 20 Wmol/l in the LF LCT
group, while the HF MCT and HF LCT plasma non-esteri¢ed
fatty acid levels averaged 249R 34 and 274R 26 Wmol/l respec-
tively. These di¡erences did not reach statistical signi¢cance.
3.3. UCP3 protein content
Basal UCP3 protein levels in WGM were approximately
4.5-fold higher than the SM and V13-fold higher compared
to CM (550R 102 vs. 118R 42 and 42R 17 arbitrary units, in
WGM vs. SM and CM respectively, P6 0.005). Thus, CM
displayed the lowest UCP3 protein levels, which were 2.8-
fold lower than SM UCP3 protein levels (118R 42 vs.
42R 17 arbitrary units), although the latter di¡erence failed
to reach statistical signi¢cance (Fig. 1).
High-fat LCT feeding signi¢cantly increased UCP3 protein
content in WGM by 2-fold in comparison with the low-fat
diet (201R 36 vs. 100R 22 arbitrary units, P6 0.05), while
MCT feeding did not a¡ect UCP3 protein levels (86 R 17 vs.
100R 21 arbitrary units, NS; Fig. 2A).
UCP3 protein content in SM (Fig. 2B) increased 4.5-fold
upon HF LCT feeding compared to the control diet (451R 81
vs. 100R 46 arbitrary units, P6 0.005). Again, there was no
di¡erence in UCP3 protein levels in SM between HF MCT
feeding and the low-fat control diet (168R 58 vs. 100R 46,
NS).
CM UCP3 protein content (Fig. 2C) showed an 11.5-fold
increase after the HF LCT diet intervention (1150R 211 vs.
100R 17 arbitrary units, P6 0.001). HF MCT showed a ten-
dency towards an increase in UCP3 protein levels in CM but,
due to high variation, this increase was not statistically sig-
ni¢cant (578R 67 vs. 100R 17, NS).
Although the high-fat-induced increase in UCP3 is most
pronounced in CM, it should be kept in mind that the base-
line levels were 13-fold lower in CM compared to WGM. If
the basal di¡erences were taken into account, absolute UCP3
values after 2 weeks of HF LCT feeding would still be highest
in WGM compared to SM and CM.
3.4. mRNA analysis
After 2 weeks of dietary intervention UCP3 mRNA levels
mimicked the change in protein levels in CM and WGM.
Thus, UCP3 mRNA levels in the WGM increased by
V75% upon HF LCT feeding compared to the control diet
although this di¡erence did not reach statistically signi¢cance
(176R 40 vs. 100R 18 arbitrary units, NS). UCP3 mRNA lev-
els after HF MCT feeding were comparable to control values
(131R 35 vs. 100R 18 arbitrary units; Fig. 3B).
In CM, UCP3 mRNA levels increased 11-fold upon HF
LCT feeding compared to the low-fat control diet (1121R
Table 2
Gain of body mass and energy intake over 2 weeks of dietary intervention
Parameter LF LCT HF MCT HF LCT
Gain of body mass (g) 45.3R 1.0 44.6R 2.9 53.0R 1.5*2
Gross energy intake (kJ) 4824R88 4434R124 5727R116**22
Net energy intake (kJ) ^ 3956R116 4214R87
Energy intake per gram gain of body mass (kJ/g) ^ 91R 4 80R 22
Values are meansRS.E.M. *P6 0.05, **P6 0.001 compared to LF LCT, 2P6 0.05, 22P6 0.001 compared to HF MCT.
Fig. 1. Basal UCP3 protein levels among di¡erent muscles. Values are meanRS.E.M. *P6 0.005 compared to WGM (SM: soleus muscle).
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378 vs. 100R 18 arbitrary units, P6 0.001) whereas after HF
MCT feeding UCP3 mRNA expression in rat heart were
not signi¢cantly di¡erent from control values (333R 137 vs.
100R 18 arbitrary units, NS; Fig. 3A).
In contrast, gene expression of the well-established PPAR
responsive genes, ACS and LCAD, did not respond to either
the high-fat LCT or MCT feeding, neither in CM nor in
skeletal muscle (Fig. 3).
Fig. 2. UCP3 protein levels. Protein levels of UCP3 after dietary intervention in (A) WGM, (B) SM and (C) CM. Values are meanRS.E.M.
*P6 0.05 compared to LF LCT. #P6 0.05 compared to HF MCT (striped boxes: LF LCT; gray boxes: HF MCT; black boxes: HF LCT).
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4. Discussion
We previously hypothesized that UCP3 acts as a fatty acid
anion exporter, hence preventing accumulation of non-metab-
olizable fatty acid anions inside the mitochondrial matrix [6].
Such a function of UCP3 is of importance, as fatty acid
anions are prone to lipid peroxidation and could potentially
damage mitochondrial DNA and proteins. According to this
hypothesis, UCP3 is especially needed in muscle with low-fat
oxidative capacity. Here, we show that CM, which is charac-
terized by a very high capacity to oxidize fatty acids, dis-
played the lowest basal levels of UCP3 by far. Basal UCP3
levels in CM were approximately 13-fold lower in comparison
with the mainly glycolytic WGM, whereas UCP3 in the latter
was approximately 4.5-fold higher when compared to the oxi-
dative SM.
Recently, Russell et al. [7] quantitatively compared UCP3
protein levels in type 1, type 2a and type 2b muscle ¢bers in
human m. vastus lateralis using immuno£uorescence. In the
present study, we con¢rm these results and earlier qualitative
results from our group [15] and others [14], showing that oxi-
dative muscles express the lowest levels of UCP3 protein com-
pared to glycolytic muscle types that express high levels of
UCP3. These data support our hypothesis that UCP3 facili-
tates export of non-metabolizable fatty acids.
As reported previously [2^4], we con¢rm at the protein level
that high-fat feeding upregulates UCP3, compared to low-fat
feeding. This upregulation was most pronounced in CM (11.5-
fold) and only 2-fold in glycolytic muscle. According to our
hypothesis, the balance between fatty acid delivery to the
muscle cell and the oxidative capacity of this cell, drives
UCP3 expression. On the one hand, it could thus be reasoned
that upon high-fat feeding, the greatest changes in UCP3 pro-
tein would be expected in muscles with a low fatty acid oxi-
dation capacity, like WGM. On the other hand, it should be
noted that basal UCP3 levels in CM and SM are very low. If
basal UCP3 levels are taken into account, UCP3 protein levels
upon HF feeding are still 2.1-fold higher in WGM compared
to SM and 2.3-fold higher than CM.
Upregulation of UCP3 upon high-fat feeding is consistent
with the proposed physiological function of UCP3, since in
this condition non-metabolizable fatty acids are more likely to
reach the matrix. However, in contrast to LCFA, which need
to be activated to long chain fatty acyl-CoA by the ACS in
Fig. 3. mRNA in muscle tissue. Expression of UCP3, ACS and LCAD after dietary intervention in (A) CM and (B) WGM. Values are
meanRS.E.M. (striped boxes: LF LCT; gray boxes: HF MCT; black boxes: HF LCT).
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the cytosol, all MCFA that enter the mitochondrial matrix
can be oxidized. Therefore, accumulation of fatty acid anions
inside the mitochondrial matrix is unlikely to occur upon HF
MCT feeding and the need for UCP3 is thus diminished com-
pared to HF LCT feeding. Here we con¢rm the absence of an
upregulation of UCP3 upon the HF MCT diet [19] in skeletal
and CMs with di¡erent fat oxidative capacity, further sup-
porting our hypothesis that UCP3 acts as an exporter of
non-metabolizable fatty acid anions.
Very recently, it was suggested that UCP3 does not export
fatty acid anions but rather fatty acid peroxide anions [25].
Based on our metabolic data we cannot conclude whether
UCP3 transports fatty acid anions or fatty acid peroxide
anions, but both hypotheses state that UCP3 has an impor-
tant role in protecting mitochondria against fatty-acid-in-
duced mitochondrial damage.
An alternative explanation for the present results could be
di¡erential e¡ects of MCT vs. LCT on PPAR activation, as
the promoter of the UCP3 gene contains a PPAR responsive
element [21]. Although plasma non-esteri¢ed fatty acids were
similar on MCT and LCT diets, it is also known that espe-
cially LCFA are potent PPAR ligands while fatty acids of
medium chain length are poor PPAR activators [22,23].
Therefore, the observed upregulation of UCP3 upon HF
LCT but not on HF MCT feeding could be general PPAR-
mediated e¡ects.
However, we show that UCP3 mRNA levels in CM and
skeletal muscle displayed the same expression pattern ob-
served on the protein level, following the di¡erent dietary
interventions. In contrast, neither ACS nor LCAD showed
di¡erences in mRNA levels in reaction to the dietary inter-
ventions, in any of the muscle types studied (Fig. 3). These
results indicate that HF LCT and HF MCT feeding did not
induce di¡erent PPAR responses. Collectively, these ¢ndings
suggest that the upregulation of UCP3 upon high-fat LCT
feeding is very speci¢c, and suggest that the observed upreg-
ulation is of physiological and functional importance.
An early proposed physiological function of UCP3 was the
regulation of energy expenditure. In this context, it is impor-
tant to note that high-fat LCT feeding induced a more prom-
inent increase in body mass compared to MCT feeding, even
though net energy intake (gross energy intake minus energy
lost in feces) was similar. This observation indicates a possible
thermogenic e¡ect of MCT consumption, although we cannot
exclude the possibility that activity-induced energy expendi-
ture was di¡erent among the groups. Earlier animal studies
revealed lower weight gain and smaller adipose tissue depots
upon MCT feeding compared to a LCT diet, suggesting a
lower storage e⁄ciency of MCTs [26^29]. Recently, St-Onge
et al. [30] also reported decreased adipose tissue storage upon
a diet rich in MCTs in overweight human males. Several ani-
mal [31^33] and human [30,34^37] studies also reported a
thermogenic e¡ect of MCT ingestion. In addition, MCTs
are rapidly absorbed in the intestine and preferentially oxi-
dized. The increased intestinal uptake was con¢rmed by our
results since MCT fed animals showed a signi¢cantly lower
fecal energy loss than LCT fed animals. Together these data
suggest a lower storage e⁄ciency and thermogenic e¡ect of
MCTs. Importantly, this MCT-induced thermogenesis occurs
while a signi¢cant upregulation of UCP3 is lacking. If the
primary role of UCP3 were to regulate energy expenditure
by increasing thermogenesis one would expect a substantial
increase in the (thermogenic) HF MCT condition rather than
in the HF LCT condition. Again this ¢nding underscores our
notion that the primary role of UCP3 is not in the thermo-
genic response. Accordingly, the mechanism behind the ther-
mogenic e¡ect of MCTs does not seem to be mediated by
UCP3.
In summary, we found that UCP3 levels in CM are, as
expected, very low when compared to glycolytic skeletal
muscle. In addition, UCP3 protein levels were upregulated
in WGM, SM and CM after 2 weeks of high-fat, LCT feed-
ing. High-fat, MCT feeding did not a¡ect UCP3 protein levels
in any of these muscles. Since plasma non-esteri¢ed fatty acids
and the expression of ACS an LCAD, two PPAR responsive
genes, were similar after HF LCT and HF MCT feeding, the
e¡ects on UCP3 levels seems to be very speci¢c. Taken to-
gether, these data support our hypothesis that UCP3 acts as a
fatty acid anion exporter to prevent mitochondrial accumula-
tion of non-metabolizable fatty acids.
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